Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.08), $0.18 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $23 million versus the consensus estimate of $21.11 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.